Bristol-Myers Squibb Company R&D Expense: 1.01B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMY R&D Expense Rankings
| Overall | 1st percentile | 1854 of 1873 |
| Sector | 2nd percentile | 421 of 430 in Healthcare |
| Industry | 36th percentile | 16 of 25 in Drug Manufacturers - Major |
BMY R&D Expense Range, Past 5 Years
| Minimum | 105.30M | Sep 1989 |
| Maximum | 756.00M | Sep 2006 |
| Average |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these BMY related companies
BMY News
$BMY http://stks.co/2MSX Continues towards the Median Line of Red pitchfork, down!
about a day ago by harmongreg
about a day ago by harmongreg
Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference
Feb 08, 3:19PM Business Wire
Feb 08, 3:19PM Business Wire
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Feb 08, 6:52AM Street Insider
Feb 08, 6:52AM Street Insider
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
Feb 08, 1:30AM Business Wire
Feb 08, 1:30AM Business Wire
$AEP bullish channel long setup #trading $SPY $SPX $BMY http://chart.ly/wnu25wq
about 6 days ago by dariabarbu75
about 6 days ago by dariabarbu75
YCHARTS DIVIDEND DAILY: Dividends Are Hot – Help For Finding Some Below – But Know the Risks, Too http://stks.co/2Geb $BMY $EXC $CEG $PEP
about 6 days ago by ycharts
about 6 days ago by ycharts
$BMY http://stks.co/2Fgm Through Hagopian Trigger, next target ML of red pitchfork near 31.40
about 7 days ago by harmongreg
about 7 days ago by harmongreg
$BMY looking like forming support at 32 level on sustained volume. http://chart.ly/2psfb3p
about 11 days ago by Sirtuan
about 11 days ago by Sirtuan
$BMY setting up a perfect entry point here with tight stop. Fingers crossed
about 11 days ago by aceTR8DER
about 11 days ago by aceTR8DER
intraday $BMY pierced above & closed right @ 10DMA support trend line. possible entry in formation. http://stks.co/2CMl #dividends
about 11 days ago by stubbybrown
about 11 days ago by stubbybrown
Listen to $BMY Q4 2011 earnings call (EPS 0.63 vs est 0.55) - live at 10:30 AM, ondemand after - http://stks.co/26el
about 17 days ago by earningscast
about 17 days ago by earningscast
$BMY $CTXS have already gone red/green premkt after earnings...$POT may be next.
about 18 days ago by TER_Intraday
about 18 days ago by TER_Intraday
EBR: Watchlist/worksheet/3 Trading Ideas: $BMY $NKA $PLCE $SVM http://stks.co/26Vj
about 18 days ago by TER_Intraday
about 18 days ago by TER_Intraday
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMY | 31.90 | -0.09 | -0.28% | 54.06B |
| FMCN | 23.47 | -0.76 | -3.14% | 3.40B |
| BRCD | 5.80 | -0.14 | -2.36% | 2.85B |
| PG | 63.88 | -0.16 | -0.25% | 175.75B |
| MSFT | 30.50 | -0.28 | -0.89% | 256.53B |
| CBI | 43.42 | -0.23 | -0.53% | 4.28B |
| URRE | 0.95 | -0.08 | -7.73% | 88.89M |
| ASEI | 77.02 | 8.74 | 12.80% | 687.02M |
| CTB | 15.93 | -0.62 | -3.75% | 991.80M |
| AMAT | 12.95 | -0.16 | -1.22% | 17.06B |
